公开(公告)号：US20160235821A1

公开(公告)日：2016-08-18

申请号：US15087563

申请日：2016-03-31

申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

发明人： Mi Sun WON ,  Hyun Seung BAN ,  Bo Kyung KIM ,  Soon Woo NAM ,  Kyeong LEE ,  Young-Ju LEE ,  Hong-Sub LEE ,  Dong Uk KIM ,  Ki Cheol PARK ,  Joo-Young IM ,  Kyoung-Jin OH

IPC分类号： A61K38/44 ,  G01N33/574 ,  C12N7/00

CPC分类号： A61K38/44 ,  A61K48/005 ,  C12N7/00 ,  C12N9/004 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12Y106/02002 ,  G01N33/57492 ,  G01N2333/90209

摘要： The present invention relates to a pharmaceutical composition for treating cancer, containing cytochrome b5 reductase 3 (CYB5R3) protein as an active ingredient. Over-expression of CYB5R3 in cancer cells results in significant reduction of hypoxia-inducible factor-1α (HIF-1α) expression, which leads inhibition of cancer cells growth in vitro and in vivo. Thus, the CYB5R3 gene or protein of the present invention can be useful as an active ingredient of a pharmaceutical composition for treating cancer.

摘要翻译： 本发明涉及用于治疗癌症的药物组合物，其含有细胞色素b5还原酶3（CYB5R3）蛋白作为活性成分。 癌细胞中CYB5R3的过度表达导致缺氧诱导因子-1α（HIF-1α）表达的显着降低，这导致体外和体内癌细胞生长的抑制。 因此，本发明的CYB5R3基因或蛋白质可以用作治疗癌症的药物组合物的活性成分。